BioRad Develops Antibodies That Inhibits Daratumumab, The Drug That Reportedly “Easily Treats” Hemorrhagic Fever, From Binding To Its Receptor
Here at American Partisan, we have been recently reporting on the rumors that the Chinese are currently using the Olympics as a way to deploy a hemorrhagic fever viral attack. Obviously, that is a very serious allegation. However, given what we know about the release of COVID-19, is this really so far fetched? Regardless, I feel the need to make sure the information is put out for your consumption, and I greatly encourage further research and critical thinking. First, let’s review:
These sources allege that a hemorrhagic fever attack is currently underway as the next deadly “pandemic” to follow the Wuhan coronavirus (Covid-19). And just like the Fauci Flu, it was supposedly constructed in a laboratory, only to now be tested for “performance” on both the Chinese people and anyone in attendance at the Olympic games. (Related: A high-ranking CCP defector came forward with intelabout how communist China has a full-scale biological weapons program.)
“The virus has been altered inside a laboratory to make the incubation period longer than usual, now suspected at 3-4 weeks, in order to allow visitors to Beijing to return home with no symptoms during transit,” reports CD Media.
“The launch of the virus is following the procedure used during the launch of Covid-19, in that portions of China are infected, locked down, in an attempt to stop the transmission to the rest of China after release. This scenario gives the PLA plausible deniability.”
This new virus is said to be highly transmissible and cause bleeding through multiple orifices of the body, including skin pores.
J.D. Rucker recently interviewed the illustrious Dr. Li-Meng Yan, who told him that the Chinese Communist Party (CCP) has released a lab-manufactured hemorrhagic fever bioweapon at the Winter Olympics in Beijing.
“Before I get into the details,” Rucker writes, “it’s important to understand that she and her sources are highly credible. There have been concerted efforts to discredit her, but her claims as far back as early 2020 have invariably been proven accurate.”
Li-Meng was one of the first, if you recall, to come forward with evidence suggesting that the Wuhan coronavirus (Covid-19) was developed in a Chinese laboratory. The powers that be tried to discredit her, but her claims continue to stand the test of time.
“They tried to disprove what she’s said all along, that Peter Daszak and Anthony Fauci had intimate knowledge of the gain-of-function research that was going on in Wuhan,” Rucker adds.
“They even tried to prove she was wrong about the inefficacy of the vaccines. All of her claims have been verified and she has been vindicated multiple times.”
Given this rumor, there was an interesting piece of information that was passed on to me this morning. In the article I just quoted, it ends with the following line:
Li-Meng says that a simple cure for hemorrhagic fever is a drug by Johnson & Johnson (J&J) called Darzalex (daratumumab), which is approved to treat multiple myeloma.
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced the launch of a range of anti-daratumumab antibodies that are specific for daratumumab (Darzalex) and inhibit the binding of the drug to its target, CD38. These highly specific and high-affinity recombinant antibodies are suitable for bioanalysis and drug monitoring of daratumumab and its biosimilars.
TO BE CLEAR: BioRad announced a range of anti-daratumumab antibodies – antibodies that inhibit the binding ability of the drug that, according to Dr. Li-Meng Yan, easily treats hemorrhagic fever.
The Bio-Rad SARS-CoV-2 ddPCR Kit is a powerful diagnostic tool in the battle against COVID-19, with sensitivity and precision beyond that of qPCR assays.
The Bio-Rad SARS-CoV-2 ddPCR Test is a partition based endpoint RT-PCR test intended for the qualitative detection of nucleic acids from SARS-CoV-2 in nasopharyngeal anterior nasal and mid-turbinate nasal swab specimens, as well as nasopharyngeal wash/aspirate and nasal aspirate specimens from patients suspected of having COVID-19 by their healthcare provider.
The kit contains the 2019-nCoV CDC ddPCR Triplex Probe Assay, One-Step ddPCR Advanced Kit for Probes and SARS-CoV-2 positive and negative standards. These components are orderable individually now, and a single part number kit is in process.
The SARS-CoV-2 ddPCR Kit is optimized for use on Bio-Rad QX200 or QXDx AutoDG Droplet Digital PCR Systems. Analytic sensitivity is very high, calculated as 0.260 cp/µl to 0.351 cp/µl (cp = copies) for genetic markers, N1 and N2, using different extraction kits, without any significant loss in specificity.